Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy

Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy Invasive lobular carcinoma comprises 10–15% of all breast cancers and is increasingly recognised as a distinct and understudied disease compared with the predominant histological subtype, invasive ductal carcinoma. Hallmarks of invasive lobular carcinoma include E-cadherin loss, leading to discohesive morphology with cells proliferating in single-file strands and oestrogen receptor positivity, with favourable response to endocrine therapy. This review summarises the distinct histological and molecular features of invasive lobular carcinoma with focus on diagnostic challenges and the impact on surgical management and medical therapy. Emphasis is placed on recent advances in our understanding of the unique molecular biology of lobular breast cancer and how this is optimising our therapy approach in the clinic. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/invasive-lobular-breast-cancer-as-a-distinct-disease-implications-for-bbUmbG490f
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2019
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-00105-0
Publisher site
See Article on Publisher Site

Abstract

Invasive lobular carcinoma comprises 10–15% of all breast cancers and is increasingly recognised as a distinct and understudied disease compared with the predominant histological subtype, invasive ductal carcinoma. Hallmarks of invasive lobular carcinoma include E-cadherin loss, leading to discohesive morphology with cells proliferating in single-file strands and oestrogen receptor positivity, with favourable response to endocrine therapy. This review summarises the distinct histological and molecular features of invasive lobular carcinoma with focus on diagnostic challenges and the impact on surgical management and medical therapy. Emphasis is placed on recent advances in our understanding of the unique molecular biology of lobular breast cancer and how this is optimising our therapy approach in the clinic.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 24, 2020

References

  • Trends in incidence rates of invasive lobular and ductal breast carcinoma
    Li, CI; Anderson, BO; Daling, JR; Moe, RE
  • Invasive lobular carcinoma of the breast: incidence and variants
    Martinez, V; Azzopardi, JG
  • Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004
    Li, CI; Daling, JR
  • WHO classification of tumours of the breast
    Lakhani, SR; Ellis, IO; Schnitt, SJ; Tan, PH; Vijver, MJ
  • Changing incidence rate of invasive lobular breast carcinoma among older women
    Li, CI; Anderson, BO; Porter, P; Holt, SK; Daling, JR; Moe, RE
  • Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
    Biglia, N; Mariani, L; Sgro, L; Mininanni, P; Moggio, G; Sismondi, P
  • Postmenopausal estrogen and progestin use in relation to breast cancer risk
    Newcomb, PA; Titus-Ernstoff, L; Egan, KM; Trentham-Dietz, A; Baron, JA; Storer, BE
  • Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States)
    Newcomer, LM; Newcomb, PA; Potter, JD; Yasui, Y; Trentham-Dietz, A; Storer, BE
  • Risk factors for ductal and lobular breast cancer: results from the nurses’ health study
    Kotsopoulos, J; Chen, WY; Gates, MA; Tworoger, SS; Hankinson, SE; Rosner, BA
  • Outcome of special types of luminal breast cancer
    Colleoni, M; Rotmensz, N; Maisonneuve, P; Mastropasqua, MG; Luini, A; Veronesi, P
  • Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics
    McCart Reed, AE; Kutasovic, JR; Lakhani, SR; Simpson, PT
  • Comprehensive molecular portraits of invasive lobular breast cancer
    Ciriello, G; Gatza, ML; Beck, AH; Wilkerson, MD; Rhie, SK; Pastore, A
  • Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma
    Adachi, Y; Ishiguro, J; Kotani, H; Hisada, T; Ichikawa, M; Gondo, N
  • Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials
    Pestalozzi, BC; Zahrieh, D; Mallon, E; Gusterson, BA; Price, KN; Gelber, RD
  • Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes
    Rakha, EA; El-Sayed, ME; Powe, DG; Green, AR; Habashy, H; Grainge, MJ
  • Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes
    Wasif, N; Maggard, MA; Ko, CY; Giuliano, AE
  • Pleomorphic lobular carcinoma of the breast: a morphologically and clinically distinct variant of lobular carcinoma
    Butler, D; Rosa, M
  • Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast
    Rakha, EA; Patel, A; Powe, DG; Benhasouna, A; Green, AR; Lambros, MB
  • A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition
    Sinn, HP; Kreipe, H
  • Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness
    Birchmeier, W; Behrens, J
  • Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility
    Handschuh, G; Candidus, S; Luber, B; Reich, U; Schott, C; Oswald, S
  • Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance
    Schackmann, RC; Amersfoort, M; Haarhuis, JH; Vlug, EJ; Halim, VA; Roodhart, JM
  • Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast
    Droufakou, S; Deshmane, V; Roylance, R; Hanby, A; Tomlinson, I; Hart, IR
  • Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability
    Sarrio, D; Moreno-Bueno, G; Hardisson, D; Sanchez-Estevez, C; Guo, M; Herman, JG
  • Aberrant expression of E-cadherin in lobular carcinomas of the breast
    Silva, L; Parry, S; Reid, L; Keith, P; Waddell, N; Kossai, M
  • Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin
    Dabbs, DJ; Bhargava, R; Chivukula, M
  • The spectrum of morphomolecular abnormalities of the E-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast
    Dabbs, DJ; Kaplai, M; Chivukula, M; Kanbour, A; Kanbour-Shakir, A; Carter, GJ
  • An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas
    McCart Reed, AE; Kutasovic, JR; Vargas, AC; Jayanthan, J; Al-Murrani, A; Reid, LE
  • A pan-cancer proteomic perspective on The Cancer Genome Atlas
    Akbani, R; Ng, PK; Werner, HM; Shahmoradgoli, M; Zhang, F; Ju, Z
  • Comprehensive molecular portraits of human breast tumours
  • E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression
    Lau, MT; Klausen, C; Leung, PC
  • FOXA1 is a key determinant of estrogen receptor function and endocrine response
    Hurtado, A; Holmes, KA; Ross-Innes, CS; Schmidt, D; Carroll, JS
  • GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility
    Theodorou, V; Stark, R; Menon, S; Carroll, JS
  • Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1
    Carroll, JS; Liu, XS; Brodsky, AS; Li, W; Meyer, CA; Szary, AJ
  • Molecular portraits of human breast tumours
    Perou, CM; Sorlie, T; Eisen, MB; Rijn, M; Jeffrey, SS; Rees, CA
  • FOXA1 mutations in hormone-dependent cancers
    Robinson, JL; Holmes, KA; Carroll, JS
  • Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings
    Lopez, JK; Bassett, LW
  • Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC)
    Biglia, N; Maggiorotto, F; Liberale, V; Bounous, VE; Sgro, LG; Pecchio, S
  • Imaging features of invasive lobular carcinoma: comparison with invasive ductal carcinoma
    Kim, SH; Cha, ES; Park, CS; Kang, BJ; Whang, IY; Lee, AW
  • Invasive lobular carcinoma. Imaging features and clinical detection
    Helvie, MA; Paramagul, C; Oberman, HA; Adler, DD
  • Sonographic evaluation of infiltrating lobular carcinoma
    Butler, RS; Venta, LA; Wiley, EL; Ellis, RL; Dempsey, PJ; Rubin, E
  • Magnetic resonance imaging for invasive lobular carcinoma: is it worth it?
    Barker, SJ; Anderson, E; Mullen, R
  • Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
    Arpino, G; Bardou, VJ; Clark, GM; Elledge, RM
  • Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast
    Mathew, A; Rajagopal, PS; Villgran, V; Sandhu, GS; Jankowitz, RC; Jacob, M
  • PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast
    Thompson, ED; Taube, JM; Asch-Kendrick, RJ; Ogurtsova, A; Xu, H; Sharma, R
  • Lobular breast cancer: clinical, molecular and morphological characteristics
    Christgen, M; Steinemann, D; Kuhnle, E; Langer, F; Gluz, O; Harbeck, N
  • The role of contralateral prophylactic mastectomy in invasive lobular carcinoma
    Babiera, G; Lowy, AM; Davidson, S; Singletary, EE
  • Invasive lobular carcinoma of the breast: local recurrence after breast-conserving therapy by subtype approximation and surgical margin
    Braunstein, LZ; Brock, JE; Chen, YH; Truong, L; Russo, AL; Arvold, ND
  • Comparison of mastectomy with breast-conserving surgery in invasive lobular carcinoma: 15-year results
    Fodor, J; Major, T; Toth, J; Sulyok, Z; Polgar, C
  • Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution
    Tubiana-Hulin, M; Stevens, D; Lasry, S; Guinebretiere, JM; Bouita, L; Cohen-Solal, C
  • Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma
    Cocquyt, VF; Blondeel, PN; Depypere, HT; Praet, MM; Schelfhout, VR; Silva, OE
  • Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes
    Cristofanilli, M; Gonzalez-Angulo, A; Sneige, N; Kau, SW; Broglio, K; Theriault, RL
  • The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics
    Nagao, T; Kinoshita, T; Hojo, T; Tsuda, H; Tamura, K; Fujiwara, Y
  • Classical lobular breast carcinoma consistently lacks topoisomerase-IIalpha gene amplification: implications for the tailored use of anthracycline-based chemotherapies
    Brunello, E; Brunelli, M; Manfrin, E; Nottegar, A; Bersani, S; Vergine, M
  • Invasive lobular carcinoma: response to neoadjuvant letrozole therapy
    Dixon, JM; Renshaw, L; Dixon, J; Thomas, J
  • Primary chemotherapy with docetaxel for the management of breast cancer
    Valero, V
  • Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience
    Valero, V; Buzdar, AU; McNeese, M; Singletary, E; Hortobagyi, GN
  • Endocrine therapy for breast cancer: a model of hormonal manipulation
    Johnston, SJ; Cheung, KL
  • Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial
    Metzger Filho, O; Giobbie-Hurder, A; Mallon, E; Gusterson, B; Viale, G; Winer, EP
  • The impact of postmastectomy radiotherapy on local control in patients with invasive lobular breast cancer
    Diepenmaat, LA; Sangen, MJ; Poll-Franse, LV; Beek, MW; Berlo, CL; Luiten, EJ
  • Post-mastectomy radiation therapy for invasive lobular carcinoma: a comparative utilization and outcomes study
    Stecklein, SR; Shen, X; Mitchell, MP
  • Lumpectomy and radiation treatment for invasive lobular carcinoma of the breast
    Warneke, J; Berger, R; Johnson, C; Stea, D; Villar, H
  • Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response
    Sikora, MJ; Cooper, KL; Bahreini, A; Luthra, S; Wang, G; Chandran, UR
  • Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems
    Sikora, MJ; Jankowitz, RC; Dabbs, DJ; Oesterreich, S
  • WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines
    Sikora, MJ; Jacobsen, BM; Levine, K; Chen, J; Davidson, NE; Lee, AV
  • Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
    Li, S; Shen, D; Shao, J; Crowder, R; Liu, W; Prat, A
  • D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer
    Merenbakh-Lamin, K; Ben-Baruch, N; Yeheskel, A; Dvir, A; Soussan-Gutman, L; Jeselsohn, R
  • Activating ESR1 mutations in hormone-resistant metastatic breast cancer
    Robinson, DR; Wu, YM; Vats, P; Su, F; Lonigro, RJ; Cao, X
  • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
    Toy, W; Shen, Y; Won, H; Green, B; Sakr, RA; Will, M
  • ESR1 mutations in metastatic lobular breast cancer patients
    Desmedt, C; Pingitore, J; Rothe, F; Marchio, C; Clatot, F; Rouas, G
  • Transcription factors and chromatin proteins as therapeutic targets in cancer
    Johnston, SJ; Carroll, JS
  • Targeting FoxA1 in estrogen receptor-positive breast cancer: biological characterization of kinase regulators
    Johnston, SJ; Holmes, KA; Carroll, JS
  • FOXA1 as a therapeutic target for breast cancer
    Nakshatri, H; Badve, S
  • Overall survival with ribociclib plus endocrine therapy in breast cancer
    Im, SA; Lu, YS; Bardia, A; Harbeck, N; Colleoni, M; Franke, F
  • Overall survival with palbociclib and fulvestrant in advanced breast cancer
    Turner, NC; Slamon, DJ; Ro, J; Bondarenko, I; Im, SA; Masuda, N
  • E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer
    Bajrami, I; Marlow, R; Ven, M; Brough, R; Pemberton, HN; Frankum, J
  • Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism
    Du, T; Zhu, L; Levine, KM; Tasdemir, N; Lee, AV; Vignali, DAA
  • Immune infiltration in invasive lobular breast cancer
    Desmedt, C; Salgado, R; Fornili, M; Pruneri, G; Eynden, G; Zoppoli, G